From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Condition | Time | Assay | Number of replicates | p-value for detected significant changes |
---|---|---|---|---|
Control JSLE | 0 h | mRNA | n=13 | p=0.003 TLR2; p=0.01 S100A9 for Ctrl vs. JSLE |
Stratified JSLE: CD16b p=0.01 IFN high vs Ctrl; | ||||
p=0.02 IFN high vs IFN low | ||||
protein | n=7 control | p=0.02 TLR; p=0.03 S100A9 | ||
n=6 JSLE | ||||
phagocytosis | n=7 control | p=0.04 E.coli | ||
n=6 JSLE | ||||
IFNa | 2 h | mRNA | n=6 | p=0.03 CD16b |
7 h | protein | n=5 | p=0.02 CD16b | |
TNFa | 30min | mRNA | n=5 | n=6 required for analysis |
2 h | protein | n=6 | p=0.03 TLR2 | |
Apoptotic supernatant | 2h, 6h | mRNA | n=5 | p=0.01 CD16b |
6h | protein | n=5 | p=0.02 CD16b |